Common shares of Arbutus are listed on the NASDAQ under the symbol ABUS.
As of March 14, 2017, Arbutus had 55.0 million common shares issued and outstanding and 58.8 million shares on a fully diluted basis.
Arbutus’ fiscal year end is December 31st.
Arbutus’ Annual General and Special Meeting took place on May 24, 2017.
Arbutus’ transfer agent and registrar is:
AST Trust Company (Canada)
1066 West Hastings Street
Vancouver, BC V6E 3X1
All communication concerning transfer requirements, lost share certificates, change of address and other related matters should be directed to the transfer agent and registrar.
Arbutus’ auditors are:
KPMG LLP Chartered Accountants
Effective August 3, 2015, Tekmira Pharmaceuticals Corporation changed its corporate name to Arbutus Biopharma Corporation (“Arbutus”, ticker symbol “ABUS”), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV. The combined entity currently fields the largest portfolio of HBV product candidates in the industry and is led by an experienced and proven leadership team.
Arbutus believes it should not be classified as a PFIC for the taxable year beginning on January 1, 2016 and ending on December 31, 2016 and the previous taxable year beginning on January 1, 2015 and ending on December 31, 2015.
Arbutus will make available, upon request, a PFIC Annual Information statement for any U.S. shareholder that has previously made a qualified electing fund (“QEF”) election and requires this information to complete its IRS Form 8621. The 2016 PFIC Annual Information statement will be available by March 15, 2017.
Shareholder are urged to consult their own tax advisors concerning the overall tax consequences of the ownership of Arbutus shares arising in their own particular situations under United States Federal, State, Local or Foreign law.
Please submit your question using the form below. * Required fields